ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Akebia Therapeutics clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 51 studies whose lead sponsor is Akebia Therapeutics or the company grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Akebia Therapeutics with Boehringer Ingelheim and AstraZeneca →

Pipeline: 3 programs

Each counted once: 3 with a study Akebia Therapeutics leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Akebia Therapeutics’ own registered studies; Akebia Therapeutics’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Akebia Therapeutics’ studies test, most open studies first — 12 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 2 more

Coming up

2 of Akebia Therapeutics’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. 1J
  9. J
  10. A
  11. S
  12. O
  13. N

Add all 2 to your calendar (.ics) → With an account.

All 51 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now36%
  • Completed4078%
  • Stopped early816%Withdrawn 4 · Terminated 3 · Suspended 1

Phase

  • Phase 318
  • Phase 216
  • Phase 114
  • Phase 42

Where

  • United States38
  • Canada8
  • Australia6
  • Israel6
  • Puerto Rico5
  • Italy5

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 718
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 226

By the year each study started; 2 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Akebia Therapeutics.

  • Akebia Therapeutics
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    37 studies
  • Keryx Biopharmaceuticals
    Acquired — became part of Akebia Therapeutics, Dec 12, 2018 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    14 studies →

Focus areas

Conditions Akebia Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →